Physicians "Get Smart" - Number of Docs Using Smartphones Surges to 64% in 2009

Manhattan ResearchIn 2009, the number of physicians using smartphones surged to 64%, according to Taking the Pulse® v9.0, pharmaceutical and healthcare market research company Manhattan Research's newly released study focused on physician adoption, use, and impact of the Internet and other technologies. This group of "smart" physicians using mobile devices such as iPhones and BlackBerries increased by 20% between 2008 and 2009. In fact, the number of physicians using iPhones more than doubled in the past year alone.

Survey results indicate that physicians' increased reliance on smartphones is not cannibalizing Internet usage on computers. Rather, physicians are spending more time online overall and are using both computers and smartphones to access to the most up-to-date online medical and pharmaceutical resources at a variety of points throughout the day. Additionally, smartphone-using physicians are an important group to take note of for strategy planning, especially for brand teams looking to leverage the evolving physician media mix in building relationships with their target audiences.

"Physicians have always been advanced in terms of their mobile use", said Monique Levy, Senior Director of Research at Manhattan Research, "Nevertheless, growth in smartphone ownership in the last year is remarkable. Mobile is delivering on its promise to allow doctors to be 'always on' - which is partly why so many doctors say the Internet is essential to their practice."

Sign up for the Taking the Pulse® v9.0 Webinar
Date: Tuesday, April 21, 2009 at 11am and 3pm EDT

Manhattan Research Senior Director of Research Monique Levy will discuss the latest trends in U.S. physician use of the Internet, mobile devices, social networking, and other technologies from the newly released Taking the Pulse® v9.0 physician study and advisory service.

This year's study reveals critical shifts in the physician media mix for professional and pharma information-seeking, making the webinar a valuable session for product managers and marketers planning strategies for connecting with physicians in 2010 and beyond.

Key topics include physician trends related to the Internet, Web 2.0 technologies, email communication, PDAs/smartphones, search engines, detailing/tech-enabled sales reps, patient interaction/education, and digital health infrastructure.

Session 1: Tuesday, April 21, 11:00am EDT
Sign up here: https://www2.gotomeeting.com/register/576156547

Session 2: Tuesday, April 21, 3:00pm EDT
Sign up here: https://www2.gotomeeting.com/register/271553794

For assistance signing up for the above sessions, please contact Maureen Malloy at This email address is being protected from spambots. You need JavaScript enabled to view it. or 212-255-7799.

About Taking the Pulse® v9.0
Taking the Pulse® v9.0 is a market research and strategic advisory service focused on which technologies physicians have adopted, how they are currently using them, and how they plan to use them in the future. The study was conducted in Q1 2009 among a nationally representative sample of 1,900 practicing U.S. physicians.

Clients can further segment the broad physician market trends to derive statistically relevant insight across the following specialties: Allergists, Cardiologists, Dermatologists, Electro Physiologists, Emergency Medicine, Endocrinologists, Gastroenterologists, Surgeons, Hematology Oncologists, Infectious Disease Specialists, Medical Oncologists, Nephrologists, Neurologists, Obstetrics/Gynecologists (OB/GYNs), Ophthalmologists, Orthopedic Surgeons, Pediatricians, Primary Care Physicians (General Practice, Family Practice and Internal Medicine), Psychiatrists, Pulmonologists, Radiologists, Rheumatologists and Urologists.

In addition to the data, clients receive strategic deliverables including research reports, client briefings, and access to the Manhattan Research analyst team to answer specific questions.

For additional product and subscription information, please visit http://www.manhattanresearch.com/products/Strategic_Advisory/ttp/

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...